Oculis Holding AG (OCS)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-01 Phase3 Readout

Active Clinical Trials (3)

NCT #TitlePhaseStatusEnrollment
NCT07548632 A Clinical Study Evaluating Licaminlimab for Dry Eye Disease PHASE3 Recruiting 160
NCT07623668 Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research PHASE3 Recruiting 210
NCT05608837 Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema PHASE2 Active Not Recruiting 28

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis